tiprankstipranks
Trending News
More News >
Church & Dwight Company (CHD)
NYSE:CHD

Church & Dwight (CHD) AI Stock Analysis

Compare
968 Followers

Top Page

CHD

Church & Dwight

(NYSE:CHD)

Select Model
Select Model
Select Model
Outperform 73 (OpenAI - 5.2)
Rating:73Outperform
Price Target:
$107.00
▲(3.80% Upside)
CHD scores well on financial performance (strong free cash flow and improving leverage) and a generally positive earnings outlook (margin expansion and mid-single-digit EPS growth). The score is held back by premium valuation and technically stretched momentum (RSI/Stoch elevated), which increases near-term pullback risk.
Positive Factors
Cash generation and capital returns
Church & Dwight consistently converts earnings into cash: FY2025 FCF ~$1.09B, OCF ~$1.2B and ~127% FCF conversion. That durable cash flow funded ~$900M returned to shareholders and a dividend increase, supporting buybacks, M&A optionality and resilient capital allocation over the medium term.
Strong brand portfolio and scale
Scale across seven power brands (≈75% of sales/profits) and ARM & HAMMER’s leadership (≈$2.0B today with a $3.0B target and record laundry share) provide durable advantages: category share, shelf placement and brand equity that support pricing resilience, durable margins and repeatable growth initiatives.
Digital and international distribution expansion
E‑commerce penetration rising from 2% to 24% is a structural shift expanding direct and omnichannel reach; digital channels drove double‑digit growth and experimentation (e.g., TikTok Shop). Coupled with ~ $1.1B international business and multi‑year organic gains, this diversifies growth levers and reduces sole dependence on U.S. brick‑and‑mortar.
Negative Factors
Slowing organic revenue growth
Organic growth has materially decelerated (FY2025 organic 0.7%, reported sales +1.6%), indicating a maturing top line after prior expansion. Sustaining EPS and revenue momentum will therefore rely more on successful brand relaunches, margin recovery, bolt‑on M&A and execution — increasing operational demands over the next several quarters.
Promotional and cost pressures on margins
A structural rise in promotional activity and larger value competitors compresses pricing and mix, while input‑cost inflation (noted as a multi‑hundred basis‑point headwind) creates persistent margin risk. Durable margin expansion will require sustained productivity, pricing power or favorable mix shifts to offset these industry pressures.
Sizable absolute debt level
Although leverage metrics have improved (debt/equity and debt/EBITDA trending lower), total debt of ~ $2.2B is still sizeable in absolute terms. That indebtedness can limit strategic flexibility for large acquisitions or extended buybacks and could amplify stress if growth or margins weaken or financing costs rise.

Church & Dwight (CHD) vs. SPDR S&P 500 ETF (SPY)

Church & Dwight Business Overview & Revenue Model

Company DescriptionChurch & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.
How the Company Makes MoneyChurch & Dwight generates revenue primarily through the sale of its consumer products across various categories. The company operates in two key segments: Consumer Domestic and Consumer International. The Consumer Domestic segment accounts for the majority of revenue, driven by strong sales of household and personal care products, particularly those under the Arm & Hammer brand. The Consumer International segment extends the company's reach to global markets, contributing additional revenue through international sales. Key revenue streams include retail sales, e-commerce, and partnerships with major retailers and distributors. Church & Dwight's strategic marketing and innovation in product development, alongside effective cost management, further enhance its profitability. Additionally, the company benefits from brand loyalty and recognition, which facilitates repeat purchases and a stable consumer base.

Church & Dwight Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Breaks down revenue by different business segments, highlighting which areas are driving growth and profitability, and where there might be challenges or opportunities for expansion.
Chart InsightsChurch & Dwight's Consumer Domestic segment shows steady growth, bolstered by strategic brand expansions like TOUCHLAND. The Consumer International segment is gaining momentum, with an 8.4% sales increase in Q3 2025, driven by higher volume and pricing strategies. However, the Specialty Products Division faces challenges, with declining revenues and increased promotional competition. Management's optimistic guidance reflects confidence in overcoming these hurdles, supported by strong Q3 results and a strategic focus on high-performing brands and international markets, despite a challenging consumer environment.
Data provided by:The Fly

Church & Dwight Earnings Call Summary

Earnings Call Date:Jan 30, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:Apr 23, 2026
Earnings Call Sentiment Positive
The call balanced clear near-term headwinds (category deceleration, modest organic growth in FY2025, promotional pressure, and portfolio-driven reported-sales drag) with numerous operational strengths: strong margin recovery and outlook, exceptional cash generation and capital returns, rapid e-commerce gains, successful tariff mitigation, and accelerating momentum in priority brands (ARM & HAMMER, TheraBreath, Hero) and acquisitions (Touchland). Management provided specific 2026 targets (3%–4% organic growth, ~100 bps gross margin expansion, 5%–8% EPS growth) and emphasized M&A optionality and international scale — overall the positives and execution progress materially outweigh the challenges discussed.
Q4-2025 Updates
Positive Updates
Company Scale and Revenue
Church & Dwight reported FY2025 sales of $6.2 billion and emphasized scale across 7 power brands that drive ~75% of sales and profits.
Organic Growth Outlook and Performance
Management set a 2026 organic growth target of 3%–4%; FY2025 reported total sales grew 1.6% while full-year organic growth was 0.7% (and 2.0% when adjusting out the VMS business).
Gross Margin and EPS Outperformance
Gross margin improved materially (Q4 gross margin ~90 basis points higher year-over-year) and management expects ~100 basis points gross margin improvement in 2026. Q4 EPS beat outlook by $0.86 and was up 12% versus prior year.
Strong Cash Generation and Capital Allocation
Operating cash flow was $1.2 billion in FY2025 with free cash flow conversion ~127%. The company returned $900 million to shareholders, maintained debt/EBITDA, and announced a 4.2% dividend increase (125th consecutive year of paying dividends; 30th consecutive increase).
Tariff Mitigation and Balance Sheet Strength
Initial tariff exposure of $190 million was proactively reduced to approximately $25 million, demonstrating effective mitigation. Management reports a conservative leverage profile (~1.5x) and continued M&A optionality.
E-commerce Transformation and Digital Gains
E-commerce penetration grew from 2% to 24% over the last decade; online channels drove double-digit growth for many brands in recent periods and are a stated engine of future growth (including TikTok Shop experimentation).
Brand and Category Momentum — ARM & HAMMER
ARM & HAMMER (approx. $2.0B today) is a stated priority to grow to $3.0B with momentum in laundry (record share of 14.5%, #1 in wash loads; grew ~20 basis points of share and outpaced category by ~1%).
High-Growth Brand Performance — TheraBreath and Hero
TheraBreath achieved record rinse share (~22%) and is #2 mouthwash with ~12% household penetration (category penetration ~65%); Hero grew ~3x the acne category rate and reached a record ~19% share in 2025, both brands identified with meaningful runway.
Successful Acquisition Integration — Touchland
Touchland acquisition contributed meaningfully to Q4 and FY performance; the brand has ~4,800 store doors, 1.2M social followers, premium retail placements (Sephora, Ulta, Kohl’s), recently launched a body & hair mist, and showed strong early international response.
International Growth Track Record
International business (~$1.1B) grew ~5.5% organic in the most recent year and averaged ~8% CAGR over three years; 2026 international growth is guided around 8% with a strategy to scale recent acquisitions globally.
Negative Updates
Category Deceleration and Weak Consumer Sentiment
Underlying categories slowed in 2025 (full-year category growth ~1.8%; first half ~2.0%, second half ~1.3%) amid weak consumer confidence (noted at 5-year lows), creating a tougher demand backdrop.
Low FY2025 Organic Growth
FY2025 organic growth was modest at 0.7% (though management notes a 2.0% organic rate excluding the VMS divestiture); Q4 organic was ~0.7% and 1.8% when excluding VMS—highlighting near-term softness that requires recovery.
Reported Sales Impact from Portfolio Exits
Portfolio exits (Vitamins, Spinbrush divestitures and shutdowns like Flawless and some showerheads) removed about $400 million of revenue from the base and create a near-term drag on reported sales (guidance shows reported sales -1.5% to +0.5%).
BATISTE Performance Weakness
BATISTE declined about 2.5 share points in 2025 (brand remains #1 and #1 in loyalty, but requires a 'brand recharge' and product renovation to regain momentum).
Promotional Environment and Competitive Pressure
Elevated promotions and the rise of value competitors (some reaching $1B scale) are pressuring categories; management acknowledged the heightened promotional environment and the risk of price/mix pressure.
Inflation and Input-Cost Pressure
Input-cost inflation (natural gas, ethylene, labor) represented roughly a ~160 basis point headwind; while productivity actions offset much of this, inflation remains a continuing margin risk.
Loss of Costco Distribution for OxiClean
An OxiClean delist at Costco created a meaningful near-term headwind (noted as a first-quarter comp issue) that contributed to periodic sales volatility.
ERP / Transformation and Execution Risk
Company is progressing an SAP/S4 transformation to digitize core systems; management is confident but acknowledged the normal execution risks associated with major ERP upgrades.
Vitamins Business Underperformance & Private Label Exposure
The Vitamins business underperformed versus expectations and private-label pressure was a driver (management sold the Vitamins business); historically weighted private-label exposure was ~12% but fell to ~5% after portfolio reshaping.
Company Guidance
Management guided 2026 to organic sales growth of 3–4% (reported sales -1.5% to +0.5% reflecting roughly $400M of exited businesses and a company sales base of ~$6.2B/$6.1–6.2B outlook), with a targeted ~100 basis‑point gross‑margin improvement, marketing spend at ~11%, and EPS growth of 5–8%; they expect cash flow of ~$1.15B (after FY‑25 cash from operations of ~$1.2B and 127% FCF conversion), maintained leverage roughly 1.5x with debt/EBITDA little changed despite ~$900M returned to shareholders and a 4.2% dividend increase, and called out regional pacing of U.S. ~3% growth, International ~8% and SPD ~5%—noting Q4 sales +3.9% (Q4 organic 0.7%, ex‑VMS 1.8%; FY organic 0.7%, ex‑VMS 2.0%) and that tariff exposure has been reduced from ~$190M to ~$25M.

Church & Dwight Financial Statement Overview

Summary
Strong overall quality supported by rising free cash flow and improving leverage. Key constraint is slowing recent revenue growth and margins that, while rebounding in 2025, remain below prior-cycle peaks.
Income Statement
78
Positive
Revenue has grown steadily over the period ($4.90B in 2020 to $6.20B in 2025), though the most recent year shows much slower growth (~1%), suggesting a maturing top-line profile. Profitability is solid but volatile: net margin improved meaningfully in 2025 (~11.9%) versus 2024 (~9.6%), yet remains below the stronger levels seen in 2020–2021 (~16%). Operating profitability also rebounded in 2025 versus 2024, but overall margins have not fully returned to prior-cycle peaks, indicating some lingering cost/price-mix pressure.
Balance Sheet
74
Positive
Leverage is moderate and trending better: debt-to-equity has declined from ~0.79 (2021) to ~0.55 (2025), reflecting improved balance-sheet risk positioning. Equity has expanded versus earlier years, supporting flexibility, while returns on equity remain attractive (2025 ~18%), albeit below the unusually strong 2020–2021 range (~26%). Key watch-out is that total debt remains sizable in absolute dollars (~$2.2B), which can limit flexibility if growth slows or financing costs rise.
Cash Flow
81
Very Positive
Cash generation is a clear strength: operating cash flow and free cash flow have risen over time, with 2025 free cash flow at ~$1.09B versus ~$0.89B in 2020. Free cash flow closely tracks earnings quality (free cash flow running at ~85%–90% of net income in recent years), indicating profits are translating into cash. The main weakness is year-to-year variability in cash flow growth (including declines in 2021–2022), and operating cash flow has been below net income in each year shown, implying some working-capital or non-cash timing headwinds.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue6.20B6.11B5.87B5.38B5.19B
Gross Profit2.77B2.79B2.59B2.25B2.26B
EBITDA1.30B1.09B1.30B831.90M1.31B
Net Income736.80M585.30M755.60M413.90M827.50M
Balance Sheet
Total Assets8.91B8.88B8.57B8.35B8.00B
Cash, Cash Equivalents and Short-Term Investments409.00M964.10M344.50M270.30M240.60M
Total Debt2.21B2.41B2.61B2.85B2.73B
Total Liabilities4.91B4.52B4.71B4.86B4.76B
Stockholders Equity4.00B4.36B3.86B3.49B3.23B
Cash Flow
Free Cash Flow1.09B976.40M807.10M706.40M875.00M
Operating Cash Flow1.22B1.16B1.03B885.20M993.80M
Investing Cash Flow-616.90M-183.30M-234.30M-728.60M-682.00M
Financing Cash Flow-1.16B-343.40M-725.60M-120.90M-252.10M

Church & Dwight Technical Analysis

Technical Analysis Sentiment
Positive
Last Price103.08
Price Trends
50DMA
90.70
Positive
100DMA
87.98
Positive
200DMA
91.00
Positive
Market Momentum
MACD
3.49
Negative
RSI
72.59
Negative
STOCH
93.93
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CHD, the sentiment is Positive. The current price of 103.08 is above the 20-day moving average (MA) of 97.90, above the 50-day MA of 90.70, and above the 200-day MA of 91.00, indicating a bullish trend. The MACD of 3.49 indicates Negative momentum. The RSI at 72.59 is Negative, neither overbought nor oversold. The STOCH value of 93.93 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CHD.

Church & Dwight Risk Analysis

Church & Dwight disclosed 34 risk factors in its most recent earnings report. Church & Dwight reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Church & Dwight Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
$364.54B23.2431.58%2.92%1.23%17.97%
73
Outperform
$24.30B34.0417.62%1.38%1.45%42.04%
69
Neutral
$156.18B22.9932.63%3.74%-0.30%-14.60%
65
Neutral
$77.04B36.341602.26%2.67%-0.05%2.49%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
62
Neutral
$14.90B20.135.05%-9.35%123.06%
61
Neutral
$36.48B18.12147.22%5.03%-10.04%-23.41%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CHD
Church & Dwight
103.08
-3.13
-2.95%
CLX
Clorox
123.60
-24.98
-16.81%
CL
Colgate-Palmolive
95.09
7.15
8.13%
KMB
Kimberly Clark
109.02
-25.51
-18.96%
PG
Procter & Gamble
160.78
-5.21
-3.14%
UL
Unilever
73.23
14.89
25.52%

Church & Dwight Corporate Events

Business Operations and StrategyM&A Transactions
Church & Dwight Sells VitaFusion and L’il Critters Brands
Neutral
Dec 9, 2025

On December 9, 2025, Church & Dwight Co., Inc. announced a definitive agreement to sell its VitaFusion® and L’il Critters® brands to Piping Rock Health Products, Inc. This transaction, which includes related trademarks, licenses, and manufacturing facilities in Vancouver and Ridgefield, Washington, is expected to close by the end of the year, subject to customary conditions. The sale is part of a strategic review of the company’s vitamin, minerals, and supplement business, which represents less than 5% of its anticipated 2025 net sales. Church & Dwight anticipates a one-time, after-tax charge of $40 million to $45 million in the fourth quarter of 2025 due to this transaction. The sale is expected to strengthen the company’s portfolio and allow a greater focus on its remaining power brands.

The most recent analyst rating on (CHD) stock is a Buy with a $102.00 price target. To see the full list of analyst forecasts on Church & Dwight stock, see the CHD Stock Forecast page.

Business Operations and StrategyExecutive/Board Changes
Church & Dwight Updates Board Tenure Guidelines
Neutral
Dec 5, 2025

On December 4, 2025, Church & Dwight Co., Inc.’s Board of Directors approved an amendment to their Corporate Governance Guidelines, removing the limits on the number of years a Board member may serve. This change aligns with the practices of many of its peers and most of the S&P 500, aiming to balance board refreshment with continuity and experience by evaluating tenure on a case-by-case basis.

The most recent analyst rating on (CHD) stock is a Buy with a $102.00 price target. To see the full list of analyst forecasts on Church & Dwight stock, see the CHD Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 02, 2026